VeriMom¿Es oligopeptide-126 sh-oligopeptide-1 seguro durante el embarazo?
No harmonised CLP reproductive classifications (ECHA Annex VI) or CIR/SCCS safety opinions identify reproductive or developmental hazard for cosmetic use of EGF/oligopeptide ingredients. Peer‑reviewed literature documents biological activity of EGF in tissues but does not provide evidence of maternal reproductive toxicity following topical cosmetic use; dermal bioavailability of large peptides is expected to be negligible (sources: ECHA Annex VI (no harmonised H360/H361), CIR/SCCS absence of adverse findings in cosmetic peptide assessments, PubMed literature on EGF topical use).
Related ingredients
Frequently asked questions
- ¿Es oligopeptide-126 sh-oligopeptide-1 seguro durante el embarazo?
- No harmonised CLP reproductive classifications (ECHA Annex VI) or CIR/SCCS safety opinions identify reproductive or developmental hazard for cosmetic use of EGF/oligopeptide ingredients. Peer‑reviewed literature documents biological activity of EGF in tissues but does not provide evidence of maternal reproductive toxicity following topical cosmetic use; dermal bioavailability of large peptides is expected to be negligible (sources: ECHA Annex VI (no harmonised H360/H361), CIR/SCCS absence of adverse findings in cosmetic peptide assessments, PubMed literature on EGF topical use).
- ¿Es oligopeptide-126 sh-oligopeptide-1 seguro durante la lactancia?
- No evidence from regulatory sources or peer‑reviewed studies that topical oligopeptide‑1 causes reproductive or lactation toxicity or transfers into breastmilk after cosmetic topical use; expected negligible systemic absorption of large peptides reduces lactational exposure (sources: PubMed, CosIng, PubChem entries for peptide cosmetic ingredients; no harmonised CLP classifications).
- ¿Es oligopeptide-126 sh-oligopeptide-1 seguro para la piel del bebé?
- Hazard and mechanism: no specific developmental or reproductive hazard shown for topical oligopeptide‑1 (h=0,m=0). Exposure: increase by +1 for infants because skin barrier immaturity can increase dermal uptake compared with adults; although large peptides have low dermal penetration, measurable absorption cannot be ruled out for compromised/immature skin, so e=1 for 0–3 yr (sources: general dermal pharmacokinetic principles in PubMed, CosIng listing of peptide cosmetic use; no specific infant studies found).
- ¿Cómo puntúa VeriMom a oligopeptide-126 sh-oligopeptide-1?
- VeriMom puntúa oligopeptide-126 sh-oligopeptide-1 en 100/100 (sin riesgos conocidos) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a oligopeptide-126 sh-oligopeptide-1 en el embarazo?
- Consulta nuestra lista de alternativas seguras a oligopeptide-126 sh-oligopeptide-1 según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.